Workflow
Brands business
icon
Search documents
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
Globenewswire· 2025-07-02 10:50
Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [2] - The company aims to deliver sustainable growth through its Rare Disease business, Generics business, and Brands business [2] Recent Developments - Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8, 2025, in Boston, MA [1]
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
GlobeNewswire News Room· 2025-03-03 21:30
Core Viewpoint - ANI Pharmaceuticals, Inc. has received FDA approval for a new prefilled syringe format of Purified Cortrophin® Gel, enhancing patient administration convenience and reflecting the company's commitment to rare disease therapies [1][2]. Product Details - The new prefilled syringe will be available in two single-dose options: 40 USP units/0.5 mL and 80 USP units/mL, alongside existing vial formats of 5 mL and 1 mL [1]. - Cortrophin Gel is indicated for various conditions, including acute gouty arthritis, rheumatoid arthritis, systemic lupus erythematosus, and severe allergic and inflammatory conditions [4]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and commercializing innovative therapeutics, particularly in rare diseases, ophthalmology, rheumatology, nephrology, neurology, and pulmonology [6]. - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [6].